Try our beta test site
11 studies found for:    Northwestern AND Irritable bowel syndrome
Show Display Options
Rank Status Study
1 Unknown  Manipulation of Visceral Sensitivity and Immune System in IBS
Condition: Irritable Bowel Syndrome
Intervention: Drug: probiotic (bacterial/dietary supplement)
2 Active, not recruiting Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Interventions: Behavioral: Self Administered Cognitive Behavior Therapy;   Behavioral: Therapist Administered Cognitive Behavior Therapy;   Behavioral: Behavioral Education and Supportive Therapy
3 Completed Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Condition: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Drug: Asimadoline;   Drug: Placebo
4 Completed Observational Study of Control Participants for the MAPP Research Network
Conditions: Fibromyalgia;   Irritable Bowel Syndrome;   Fatigue Syndrome, Chronic
Intervention:
5 Completed
Has Results
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Interventions: Drug: LX1031 High Dose;   Drug: LX1031 Low Dose;   Drug: Placebo
6 Completed Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Intervention: Drug: Rifaximin
7 Completed Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Interventions: Drug: Asimadoline;   Drug: Placebo
8 Completed A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Intervention: Drug: Dextofisopam
9 Completed LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Condition: Irritable Bowel Syndrome
Intervention:
10 Recruiting Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
11 Completed ETEC Logistics Trial (TREK)
Condition: Diarrhea
Interventions: Biological: Heat-Labile Enterotoxin of Escherichia coli (LT);   Biological: Placebo

Study has passed its completion date and status has not been verified in more than two years.